InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China
Press release content from Business Wire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Med Sci. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Teclistamab is the first T-cell redirecting bispecific antibody to receive a positive CHMP opinion for adults with RRMM and highlights Janssen's commitment to innovation in multiple myeloma The
Assessing key research trends in virtual learning during the COVID-19 pandemic through a bibliometric analysis of 1595 studies from 589 journals during 2020-21
Will a time-tested intervention such as acupuncture point your health in the right direction, or is it a ...
Why protecting the ‘master controller’ of our metabolism is key to health and wellbeing; and how classing thyroid disorders as noncommunicable diseases (NCDs) can help.